Great Arab Minds award winner revolutionizes global water access
Dubai, United Arab Emirates: Professor Omar Yaghi, a distinguished Professor of Chemistry at the University of California, Berkeley, and the Visionary Founder of Water Harvesting Inc. (WaHa), has been awarded the Great Arab Minds Award in Natural Sciences for 2024 by H.H Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Dubai Ruler. This prestigious recognition marks another milestone in Professor Yaghi's groundbreaking career in reticular chemistry.
Frank Ramirez, CEO of WaHa, comments:
"Professor Yaghi's Great Arab Minds Award is a well-deserved recognition of his pioneering work in reticular chemistry. His groundbreaking research has not only advanced the field of materials science but has also opened new frontiers in addressing global challenges like water scarcity. This award underscores the profound impact of Professor Yaghi's contributions to science and society."
Chris Kay, President of WaHa, comments:
"We are thrilled to be implementing Professor Yaghi's revolutionary technology in the UAE through our WaHa Vaporator®. This innovative system aligns perfectly with the UAE's forward-thinking sustainability goals, producing pure drinking water even in the challenging desert climate. Our successful pilots in the region demonstrate the practical application of this technology, offering a sustainable solution to water scarcity that could transform lives across the Middle East and beyond."
Professor Omar Yaghi's Laboratory, UC Berkeley
Professor Omar Yaghi leads a world-renowned research group in the Department of Chemistry at UC Berkeley. The lab specializes in reticular chemistry, focusing on developing Metal-Organic Frameworks (MOFs) and Covalent Organic Frameworks (COFs). The Laboratory is at the forefront of creating sustainable solutions for global energy, environment, and water scarcity challenges. Their work has applications in clean energy, gas storage, carbon capture, and water harvesting from air.
This has led to over 300 publications and 250,000 citations, and the receipt by Professor Yaghi of numerous recognitions - the Albert Einstein World Award of Science (2017), the Wolf Prize in Chemistry (2018); the Gregory Aminoff Prize (2019); the VinFuture Prize (2022), and the Science for the Future Ernest Solvay Prize (2024)
WaHa Inc:
WaHa is a pioneering climate technology company revolutionizing the cooling and atmospheric water generation (AWG) industries. At the heart of WaHa's innovation is the patented WaHa Vaporator® technology, a groundbreaking and disruptive platform for solid desiccant regeneration in the air conditioning, dehumidification, and AWG markets.
Source: AETOSWire
Contacts:
Satish Chandran
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Al Etihad
03-06-2025
- Al Etihad
M42, AstraZeneca, SOPHiA GENETICS to transform cancer diagnosis, care
3 June 2025 14:30 ABU DHABI (ALETIHAD)M42, a global health leader powered by technology, announced a strategic collaboration with AstraZeneca and SOPHiA GENETICS to bring cutting-edge liquid biopsy testing to the UAE, aimed at advancing cancer diagnosis, informing treatment decisions, and enabling faster, accurate biomarker testing across a broad range of part of the collaboration, M42 will integrate SOPHiA GENETICS' MSK-ACCESS®, powered with SOPHiA DDM™ technology, into its testing infrastructure, enabling non-invasive genomic profiling of cancers through a simple blood approach does not replace but rather complements routine cancer screenings, and is designed for patients who are unable to undergo a solid tumor biopsy, enabling them to be matched with a precision therapy tailored to their specific cancer the next 12 months, the partnership will enable liquid biopsy testing access across select leading hospitals across the UAE, providing patients with faster, less invasive biomarker insights compared to traditional tissue biopsies, while also strengthening testing infrastructure and capabilities for a wide range of cancers in the new testing programme will initially target lung, ovarian, breast, colorectal, and pancreatic cancers, among others, addressing some of the most critical cancer burdens in the studies are set to commence shortly at Cleveland Clinic Abu Dhabi, marking a key milestone toward the full clinical launch planned for the latter part of Q2 El-khani, Senior Vice President, Operations, Integrated Health Solutions at M42, said, 'This collaboration reflects our vision of democratising health by making advanced diagnostics accessible to more patients, supporting not just early diagnosis but also real-time treatment monitoring and cost-effective, precise, predictive, and personalised care.'Sameh El Fangary, Cluster President GCC of AstraZeneca, stated, "Our work, and our collaborations with partners across industry, are driving towards better treatments for patients as well as a more sustainable future for healthcare systems. Through our latest partnerships, we are committed to transforming cancer care for millions in the region by advancing early diagnosis and optimising patient pathways from detection to therapy.' Ross Muken, President of SOPHiA GENETICS, said, "Expanding access to advanced testing technologies is central to our mission at SOPHiA GENETICS. Partnering with M42 and AstraZeneca in the UAE allows us to equip healthcare providers with the tools they need to personalise care, monitor disease in real-time, and ultimately improve outcomes for patients across the region." Source: Aletihad - Abu Dhabi
Arabian Post
19-05-2025
- Arabian Post
LiveSpo® NAVAX Nasal-Spray Probiotics: A New Approach in Supporting the Treatment of Rhinosinusitis and Otitis Media
The findings from the clinical study, conducted Thai Binh University of Medicine and Pharmacy in collaboration with other institutions, was published on January 27, 2025, in Scientific Reports-Nature, a renowned journal under the Nature Portfolio (UK). The results demonstrated significant effectiveness in children within just 3–7 days of use. Additionally, data also showed positive improvements in adults, highlighting the product's potential for broader application in the future. The study was carried out from November 2023 to December 2024 with the participation of 126 patients, including both children and adults. Among children with acute rhinosinusitis and perforated acute otitis media, the treatment results were particularly notable: after 3 days of using LiveSpo® NAVAX, nasal congestion decreased by 68%, twice as much as the saline group. After 7 days, 97% of the children had no more nasal discharge, and 100% had no more ear discharge. The concentration of pathogenic bacteria Streptococcus pneumoniae in nasal and ear secretions dropped more than 1,200 times. Importantly, no side effects were recorded during the entire trial – even in children with weakened immune systems. In the adult group with acute sinusitis, symptoms such as nasal congestion, facial pain, and purulent discharge improved significantly after 3 days of use – with reductions of 53%, 78%, and 61%, respectively. After 7 days, 91% of patients no longer experienced nasal discharge. Laboratory results showed a substantial reduction in pathogenic bacteria: Streptococcus pneumoniae decreased over 380-fold and Haemophilus influenzae decreased over 49,000-fold compared to the Control group receiving physiological saline According to the research team, the effectiveness of LiveSpo® NAVAX origins from its ability to modulate local inflammatory responses and enhance mucosal immunity through the competitive biological mechanism of spore-forming Bacillus probiotics. Inflammatory markers such as IL-6, IL-8, and TNF-α significantly decreased, while levels of IgA – a key protective antibody at the mucosal surface – increased, contributing to the restoration of the nose and ear's natural defense barrier. This study not only adds to the growing body of scientific evidence supporting LiveSpo® NAVAX's efficacy in respiratory care but also affirms Vietnam's biomedical research capabilities on the international scientific map. It paves the way for a safe, sustainable respiratory treatment alternative that reduces reliance on antibiotics – especially for vulnerable groups like children. Dr. Nguyen Hoa Anh, Chairman and Founder of LiveSpo Pharma, shared: 'At LiveSpo, we prioritize the research and development of internationally standardized products, combining modern medicine with advanced probiotic technology to deliver safe and effective health solutions for the community – all with a vision of A Future Without Antibiotics.' References: Khieu TH, Le DP, Nguyen BT, Ngo BT, Chu HT, Truong DM, Nguyen HM, Nguyen AH, Pham TD, Van Nguyen AT. Alleviating symptoms of paediatric acute rhinosinusitis and acute otitis media with otorrhea using nasal-spraying Bacillus probiotics: a randomized controlled trial. Sci Rep. 2025 Jan 27;15(1):3410. doi: 10.1038/s41598-025-87372-2. PMID: 39870748; PMCID: PMC11772584. Hashtag: #LiveSpo The issuer is solely responsible for the content of this announcement. About LiveSpo Pharma LiveSpo is an R&D, manufacturing, and distribution brand of Clinically Proven Medical Probiotics, leading in breakthrough technology, rapid effectiveness, and convenience, aiming for 'A Future Without Antibiotics'. Our vision: In 2027, LiveSpo will have 1.5 million consumers who use Spore probiotics for digestive and respiratory health instead of antibiotics, with outstanding benefits and customer experiences. Established since 2010 by Dr. Nguyen Hoa Anh (Dr. ANH) and his colleagues, LiveSpo has remained steadfast in its belief that Live Probiotic Spores – Spobiotic – will pave the way to a future without antibiotics for everyone. Hotline: 1800.088808 Website:
Emirates Woman
01-05-2025
- Emirates Woman
This ultra-rare colour is so exclusive only five people have ever seen it
Imagine a colour so extraordinary, it exists outside the boundaries of natural vision. A luminous blue-green hue so vivid, it makes the most saturated neon signs look washed out. Olo is the first new color discovered in centuries, witnessed by just five pioneering scientists who volunteered to have lasers shot directly into their eyes in the name of discovery. The colour cannot be seen with the naked eye, but the five people who have seen it describe it as being similar to teal. What if some colors are invisible not because they're rare, but because we physically can't see them? UC Berkeley scientists discovered Olo – a hue that can't be rendered, only experienced. Olo may never join the Pantone Color System… or will it? — PANTONE (@pantone) April 23, 2025 In a University of California laboratory, researchers achieved what was previously thought impossible. They tricked the human eye into perceiving a colour beyond nature's spectrum. By using precisely calibrated laser pulses to stimulate individual colour receptors in the retina, they created a visual experience never before recorded in human history. Professor Ren Ng, one of the study's authors and brave participants, describes olo as 'more intense than any color found in the physical world.' The effect was so startling that scientists developed special equipment just to verify its existence, with participants matching the hue against adjustable colour dials. While the discovery sparks immediate visions of avant-garde fashion collections and futuristic interior design, the implications run deeper. For instance, imagine olo-accented Birkins. This breakthrough could revolutionize how we understand colour blindness, potentially leading to technologies that help those who see the world differently. The scientific process behind 'olo' In a study published in Science Advances on April 18, professors from UC Berkeley and the University of Washington School of Medicine revealed their groundbreaking discovery: a hue beyond the limits of human vision. A clever technique named Oz their secret. It is an homage to the Wizard of Oz—that 'tricks' the eye into perceiving the impossible. Just as the Wizard used emerald glasses to make his fictional city appear more dazzling, the Oz device uses precisely calibrated lasers to stimulate individual color receptors in the retina. The result? Olo, a shade so radically new that the brain has no natural reference for it. Professor Ren Ng, one of the study's authors and intrepid participants, describes the experience as 'more intense than any color found in the physical world.' To confirm their findings, researchers had participants match the elusive hue against adjustable colour dials—proving that olo wasn't just a fleeting illusion, but a documented scientific first. As researchers continue exploring olo's potential, one thing is certain: the human experience of colour just became infinitely more fascinating. The next time you admire a vibrant painting or a tropical ocean vista, remember – there are still visual wonders waiting to be discovered. – For more on luxury lifestyle, news, fashion and beauty follow Emirates Woman on Facebook and Instagram Images & Feature Image: Pinterest
